Fosun Pharma (2196.HK) Increases Stake in Genetic Testing Unicorn to 60%
【Abstract】: (Corporate Action) Fosun Pharma has announced an additional investment to acquire a controlling 60% stake in a leading domestic reproductive genetics firm. The move integrates upstream reagent manufacturing with Fosun’s downstream hospital network, creating a closed-loop "Diagnosis + Treatment" ecosystem.
Business Insight: Vertical integration is the trend for 2026. Standalone genetic testing labs are being swallowed by large hospital groups or pharma giants. For smaller players, the exit strategy is shifting from "IPO" to "M&A." This consolidation helps large groups control costs and capture the full lifetime value of the fertility patient.
【Keywords】: #FosunPharma #VerticalIntegration #GeneticTestingMarket
